1
|
Brancaccio D, Di Maro S, Cerofolini L, Giuntini S, Fragai M, Luchinat C, Tomassi S, Limatola A, Russomanno P, Merlino F, Novellino E, Carotenuto A. HOPPI-NMR: Hot-Peptide-Based Screening Assay for Inhibitors of Protein-Protein Interactions by NMR. ACS Med Chem Lett 2020; 11:1047-1053. [PMID: 32435424 DOI: 10.1021/acsmedchemlett.9b00620] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 02/20/2020] [Indexed: 12/23/2022] Open
Abstract
Protein-protein interactions (PPIs) contribute to the onset and/or progression of several diseases, especially cancer, and this discovery has paved the way for considering disruption of the PPIs as an attractive anti-tumor strategy. In this regard, simple and efficient biophysical methods for detecting the interaction of the inhibitors with the protein counterpart are still in high demand. Herein, we describe a convenient NMR method for the screening of putative PPI inhibitors based on the use of "hot peptides" (HOPPI-NMR). As a case study, HOPPI-NMR was successful applied to the well-known p53/MDM2 system. Our outcomes highlight the main advantages of the method, including the use of a small amount of unlabeled proteins, the minimization of the risk of protein aggregation, and the ability to identify weak binders. The last leaves open the possibility for application of HOPPI-NMR in tandem with fragment-based drug discovery as a valid strategy for the identification of novel chemotypes acting as PPI inhibitors.
Collapse
Affiliation(s)
- Diego Brancaccio
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| | - Salvatore Di Maro
- DISTABIF, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
| | | | | | - Marco Fragai
- CERM, University of Florence, 50019 Sesto Fiorentino, Italy
| | | | - Stefano Tomassi
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| | - Antonio Limatola
- Department of Biology, Stanford University, Stanford, California 94305-5430, United States
| | - Pasquale Russomanno
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| | - Francesco Merlino
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| | - Ettore Novellino
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| | - Alfonso Carotenuto
- Department of Pharmacy, University of Naples “Federico II”, 80131 Naples, Italy
| |
Collapse
|
2
|
Giacomelli C, Natali L, Trincavelli ML, Daniele S, Bertoli A, Flamini G, Braca A, Martini C. New insights into the anticancer activity of carnosol: p53 reactivation in the U87MG human glioblastoma cell line. Int J Biochem Cell Biol 2016; 74:95-108. [DOI: 10.1016/j.biocel.2016.02.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 02/18/2016] [Accepted: 02/22/2016] [Indexed: 12/31/2022]
|
3
|
Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep 2014; 4:4749. [PMID: 24756113 PMCID: PMC3996484 DOI: 10.1038/srep04749] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Accepted: 04/03/2014] [Indexed: 12/26/2022] Open
Abstract
In the complex scenario of cancer, treatment with compounds targeting multiple cell pathways has been emerging. In Glioblastoma Multiforme (GBM), p53 and Translocator Protein (TSPO), both acting as apoptosis inducers, represent two attractive intracellular targets. On this basis, novel indolylglyoxylyldipeptides, rationally designed to activate TSPO and p53, were synthesized and biologically characterized. The new compounds were able to bind TSPO and to reactivate p53 functionality, through the dissociation from its physiological inhibitor, murine double minute 2 (MDM2). In GBM cells, the new molecules caused Δψm dissipation and inhibition of cell viability. These effects resulted significantly higher with respect to those elicited by the single target reference standards applied alone, and coherent with the synergism resulting from the simultaneous activation of TSPO and p53. Taken together, these results suggest that TSPO/MDM2 dual-target ligands could represent a new attractive multi-modal opportunity for anti-cancer strategy in GBM.
Collapse
|